Literature DB >> 25709933

When important steps for a reliable meta-analysis are missing: the bevacizumab versus ranibizumab case.

Valentino Conti1, Mauro Venegoni1, Ugo Moretti2, Corrado Barbui3.   

Abstract

Entities:  

Year:  2015        PMID： 25709933      PMCID： PMC4325267          DOI： 10.3980/j.issn.2222-3959.2015.01.35

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  7 in total

1.  Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis.

Authors:  Xiao-Yu Zhang; Xiao-Fan Guo; Shao-Dan Zhang; Jing-Na He; Cao-Yu Sun; Yin Zou; Han-Si Bi; Yang Qu
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

2.  A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

Authors:  Ilse Krebs; Leopold Schmetterer; Agnes Boltz; Reinhard Told; Veronika Vécsei-Marlovits; Stefan Egger; Ulrich Schönherr; Anton Haas; Siamak Ansari-Shahrezaei; Susanne Binder
Journal:  Br J Ophthalmol       Date:  2013-01-03       Impact factor: 4.638

3.  Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.

Authors:  Sanjay Sharma; Davin Johnson; Marwan Abouammoh; Simon Hollands; Ashley Brissette
Journal:  Can J Ophthalmol       Date:  2012-06       Impact factor: 1.882

4.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

5.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal:  Lancet       Date:  2013-07-19       Impact factor: 79.321

6.  Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Authors:  Laurent Kodjikian; Eric H Souied; Gérard Mimoun; Martine Mauget-Faÿsse; Francine Behar-Cohen; Evelyne Decullier; Laure Huot; Gilles Aulagner
Journal:  Ophthalmology       Date:  2013-08-02       Impact factor: 12.079

7.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.